Logo

CNTA

Centessa Pharmaceuticals plc

CNTA

Centessa Pharmaceuticals plc • NASDAQ
$29.03 ▲ 0.17% (+0.05)
Market Cap $3.90 B
52w High $29.99
52w Low $9.60
Dividend Yield 0%
P/E -15.36
Volume 1.22M
Outstanding Shares 134.42M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $53.79M ▼ $-54.891M ▼ 0% $-0.41 ▼ $-51.598M ▼
Q2-2025 $0 ▼ $54.653M ▲ $-50.343M ▼ 0% ▲ $-0.38 ▼ $-46.455M ▼
Q1-2025 $15M ▲ $45.777M ▼ $-26.135M ▲ -174.233% ▼ $-0.2 ▲ $-21.644M ▲
Q4-2024 $0 $74.58M ▲ $-111.329M ▼ 0% $-0.84 ▼ $-107.57M ▼
Q3-2024 $0 $46.405M $-42.566M 0% $-0.37 $-39.165M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $246.214M ▼ $448.3M ▼ $146.726M ▼ $301.574M ▼
Q2-2025 $250.724M ▼ $492.127M ▼ $147.208M ▲ $344.919M ▼
Q1-2025 $284.505M ▼ $527.845M ▼ $141.598M ▼ $386.247M ▼
Q4-2024 $482.177M ▼ $576.798M ▼ $175.253M ▲ $401.545M ▼
Q3-2024 $518.449M $609.715M $110.578M $499.137M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-54.891M ▼ $-58.312M ▼ $61.945M ▲ $3.437M ▲ $6.569M ▲ $-58.546M ▼
Q2-2025 $-50.343M ▼ $-22.452M ▲ $-39.954M ▲ $1.605M ▼ $-60.914M ▲ $-22.578M ▲
Q1-2025 $-26.135M ▲ $-57.246M ▼ $-222.388M ▼ $3.086M ▲ $-278.065M ▼ $-57.246M ▼
Q4-2024 $-111.329M ▼ $-42.8M ▼ $25M ▼ $2.963M ▼ $-11.805M ▼ $-42.8M ▼
Q3-2024 $-42.566M $-21.389M $44.964M $245.983M $267.654M $-21.423M

Revenue by Products

Product Q1-2025
Reportable Segment
Reportable Segment
 $10.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Centessa is still very much a development‑stage biotech: it essentially has no product revenue, and its income statement is dominated by research and development and overhead costs. That means recurring operating losses each year are expected, not surprising. Losses have been fairly consistent over the past few years rather than rapidly escalating, which suggests some cost discipline, but the company is still a long way from profitability and will likely remain loss‑making until it either secures partnerships or brings a drug to market.

Balance Sheet

Balance Sheet The balance sheet shows a classic early‑stage biotech profile: plenty of cash relative to its small size, modest debt, and positive shareholders’ equity. Cash levels dipped and then were rebuilt, likely through financing or other capital raises, which is common for this type of company. Debt appears manageable compared with cash and equity, so the capital structure does not look overly stressed. Overall, the company seems to be funding its research mainly with equity and cash on hand rather than heavy borrowing.

Cash Flow

Cash Flow Cash flow is consistently negative from operations, which reflects ongoing spending on clinical trials, staff, and other R&D activities without offsetting revenue. Free cash flow closely tracks operating cash flow because the business is not capital‑intensive and spends very little on physical assets. The key question for Centessa is how long its cash reserves can support this burn rate; current disclosures suggest a multi‑year runway, but over time the company will almost certainly need either new capital or partnering income if products have not yet reached the market.

Competitive Edge

Competitive Edge Centessa operates in highly competitive, innovation‑driven niches: sleep‑wake disorders through its orexin agonist programs, and cancer immunotherapy through its LockBody platform. It competes against large, well‑funded pharma companies in both spaces, which is a clear challenge. Its edge lies in its asset‑centric structure—small, focused teams around each drug candidate—and in differentiated science, such as highly selective orexin agonists and conditionally activated antibodies that aim to reduce toxicity. The portfolio approach helps spread development risk across several programs, but the company’s ultimate standing will depend on how compelling its clinical data look versus rival drugs.

Innovation and R&D

Innovation and R&D R&D is the heart of Centessa. The company’s asset‑centric model is designed to push each promising molecule forward quickly while being willing to stop weaker programs early. Its orexin program targets a well‑understood biological pathway for narcolepsy and other sleep disorders, with multiple candidates building a potential franchise. The LockBody platform is more experimental but could be powerful if it truly improves the safety and precision of cancer immunotherapies. Heavy and sustained R&D spending is intentional and explains the ongoing losses; the pay‑off, if it comes, would be regulatory approvals or attractive partnering deals, but clinical and regulatory risks remain high at this stage.

Summary

Centessa is a young, clinical‑stage biotech focused on a few high‑potential areas rather than a broad, early‑research portfolio. Financially, it is a pre‑revenue company that runs steady operating losses and negative cash flow by design, supported by a balance sheet with more cash than debt and a stated runway that extends several years. Strategically, its differentiation rests on an asset‑centric operating model and innovative platforms in orexin biology and conditional immuno‑oncology. The main opportunities lie in positive clinical results that validate these platforms and attract partners; the main risks are the usual ones for biotech—trial setbacks, delays, or safety issues, plus the eventual need to raise more capital if commercial revenues do not materialize in time.

NEWS

November 11, 2025 · 8:40 PM UTC

Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Read more

November 11, 2025 · 4:00 PM UTC

Centessa Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares

Read more

November 7, 2025 · 8:00 AM UTC

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Read more

November 5, 2025 · 7:00 AM UTC

Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2025 and Provides Update on Potential Best-in-Class Orexin Receptor 2 (OX2R) Agonist Program

Read more

September 3, 2025 · 7:00 AM UTC

Centessa Pharmaceuticals to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Read more